Themis Bioscience GmbH
🇦🇹Austria
- Country
- 🇦🇹Austria
- Ownership
- Subsidiary
- Established
- 2009-09-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.themisbio.com
Clinical Trials
12
Active:4
Completed:7
Trial Phases
2 Phases
Phase 1:8
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Phase 1
8 (66.7%)Phase 2
4 (33.3%)A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract
Phase 1
Withdrawn
- Conditions
- Gastrointestinal Cancer
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Themis Bioscience GmbH
- Registration Number
- NCT04195373
- Locations
- 🇩🇪
University Hospital Bonn, Bonn, Germany
🇩🇪University Hospital Tübingen, Tübingen, Germany
A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Themis Bioscience GmbH
- Target Recruit Count
- 60
- Registration Number
- NCT04055454
- Locations
- 🇧🇪
University of Antwerpen, Centre for the Evaluation of Vaccination (CEV), Antwerp, Belgium
Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001)
Phase 1
Completed
- Conditions
- Zika Virus Infection
- First Posted Date
- 2019-07-25
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- Themis Bioscience GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT04033068
- Locations
- 🇦🇹
Institute of Specific Prophylaxis and Tropical Medicine, Vienna, Austria
Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)
Phase 2
Completed
- Conditions
- Chikungunya Virus Infection
- First Posted Date
- 2019-01-17
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Themis Bioscience GmbH
- Target Recruit Count
- 41
- Registration Number
- NCT03807843
- Locations
- 🇵🇷
San Juan Hospital, Research Unit, San Juan, Puerto Rico
Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)
Phase 2
Completed
- Conditions
- Chikungunya Virus Infection
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Themis Bioscience GmbH
- Target Recruit Count
- 60
- Registration Number
- NCT03635086
- Locations
- 🇬🇧
Celerion Belfast, Belfast, Northern Ireland, United Kingdom
- Prev
- 1
- 2
- Next
News
No news found